Hippocampal-Sparing Prophylactic Cranial Irradiation in Pathologically Nodal Positive Non-Small-Cell Lung Cancer

Launched by CHANG GUNG MEMORIAL HOSPITAL · May 17, 2015

Keywords

ClinConnect Summary

This clinical trial is studying a type of radiation therapy called hippocampal-sparing prophylactic cranial irradiation (PCI) for patients with non-small-cell lung cancer (NSCLC) that has spread to the lymph nodes. The goal is to see if this treatment can help prevent brain metastasis (cancer spreading to the brain) while also protecting memory and thinking skills, which can be affected by radiation. Patients eligible for this trial are adults aged 18 and older who have had surgery for their lung cancer, received chemotherapy, and have a specific type of cancer spread in their lymph nodes.

Participants in the trial will be randomly assigned to either receive the hippocampal-sparing PCI or to be monitored without the treatment. Those receiving PCI will undergo radiation therapy over three weeks, while both groups will have regular brain scans and cognitive tests to assess their memory and thinking abilities. This trial aims to gather important information about the benefits and risks of this new approach to treatment, helping to shape future care for patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of NSCLC
• • Must be adult patients (≥ 18 years old) who have received definitive surgery and have a permanent pathology of nodal metastasis
• • Platinum-based chemotherapy is mandatory
• • Good performance status better than Eastern Cooperative Group (ECOG) of 2 or a general status of Karnofsky (KPS) \> 70 %
• • Should have sufficient proficiency in Mandarin language
• Exclusion Criteria:
• • Have received prior cranial irradiation
• • Presence of other active primary cancer (exception of basal cell carcinoma of skin and cervical carcinoma in situ)
• • Radiographic evidence of brain metastasis/metastases
• • Clinical evidence of extracranial metastatic disease
• • Hypersensitivity to magnetic resonance (MR) contrast enhancer
• • Serious medical or psychiatric illness